Mushrooms & Gastric Health
1,000× reduction in H. pylori
Lion's mane mushroom extract reduced H. pylori survival 1,000-fold in a living animal model, and worked equally against antibiotic-resistant and antibiotic-susceptible strains.
Wang et al., International Journal of Medicinal Mushrooms, 2019
14 species
tested head-to-head against H. pylori by Shang 2013; lion's mane ranked first
~2 mg/mL
minimum inhibitory concentration in lab studies for lion's mane extracts
~50%
of adults globally carry H. pylori, most without symptoms
Wang et al., International Journal of Medicinal Mushrooms, 2019
View as image ↗H. pylori is the bacterium behind most stomach ulcers and the leading infectious cause of gastric cancer. Roughly half the world's adults carry it, most without obvious symptoms. When it does cause trouble, it inflames the stomach lining, a condition called gastritis, and in some people progresses to peptic ulcers or, over decades, to gastric adenocarcinoma. Standard treatment is triple therapy: two antibiotics combined with a stomach acid suppressant. But resistance to those antibiotics has risen steadily, pushing researchers toward natural compounds that might inhibit H. pylori or support the gut after treatment. For the broader context of how mushrooms interact with the digestive system, see Mushrooms as Prebiotics: How They Feed Your Gut Bacteria.
Here is what the research currently shows: multiple medicinal mushroom extracts inhibit H. pylori in lab conditions, with lion's mane (Hericium erinaceus) showing the strongest and most consistent activity. A 2013 comparative study tested 14 mushroom species against H. pylori and found lion's mane outperformed all others, with a minimum inhibitory concentration of approximately 2 mg/mL. Critically, the lion's mane extracts worked equally well against antibiotic-resistant and antibiotic-susceptible H. pylori strains. A 2019 animal study confirmed a 1,000-fold reduction in H. pylori survival at the same concentration. No human clinical trial has tested mushrooms against H. pylori in people. All evidence is preclinical.
Key Takeaways
- Shang 2013 tested 14 medicinal mushroom species against H. pylori in controlled lab conditions; lion's mane showed the strongest activity of all species, with a minimum inhibitory concentration of approximately 2 mg/mL
- Lion's mane extracts inhibited both antibiotic-resistant and antibiotic-susceptible H. pylori strains equally (Shang 2013); resistance to clarithromycin or metronidazole did not protect the bacteria from the mushroom extract
- Wang 2019 confirmed effects in a living animal model: H. pylori survival decreased 1,000-fold (3 log units) at 2 mg/mL, establishing that the effect extends beyond the petri dish
- Liu 2016 identified the specific fractions in lion's mane responsible for anti-H. pylori activity; different fractions showed different potency, meaning not all extracts or supplements are pharmacologically equivalent
- Li 2014 found lion's mane extracts inhibit human gastrointestinal cancer cell lines; Kuo 2017 showed erinacine A (a mycelium compound) reduces gastric cancer cell viability; both findings are relevant because H. pylori is the primary cause of gastric adenocarcinoma
- No human clinical trial has tested any mushroom for H. pylori eradication in people; all existing evidence comes from cell culture and animal models
The Antibiotic Resistance Problem That Made Researchers Turn to Mushrooms
H. pylori (Helicobacter pylori) is a spiral-shaped bacterium adapted to survive in the highly acidic stomach environment by burrowing into the protective mucus layer that lines the stomach wall. About half the global adult population carries it. The majority of those people will never develop serious symptoms. In a meaningful minority, though, chronic infection causes gastritis (persistent stomach lining inflammation), peptic ulcers, or, over many years, precancerous cellular changes that can progress to gastric adenocarcinoma.
The World Health Organization classifies H. pylori as a Group 1 carcinogen, the same risk category as tobacco. Treating and eradicating the infection reduces the downstream risk of gastric cancer.
For decades, the standard eradication protocol has been triple therapy: two antibiotics, usually clarithromycin and metronidazole, combined with a proton pump inhibitor to suppress stomach acid and improve the antibiotic environment. Triple therapy works well when the H. pylori strains are susceptible. The problem is that global resistance to these antibiotics has climbed sharply. Resistance to clarithromycin, one of the core components, now exceeds 20% in many regions. Metronidazole resistance rates are even higher. When triple therapy fails, second-line regimens become more complex and more difficult to complete.
This background has driven real scientific interest in natural compounds that might either inhibit H. pylori directly or serve as adjuncts: compounds used alongside antibiotics to improve eradication rates, or consumed afterward to support gut microbiome recovery. Medicinal mushrooms entered this research space because of their known antimicrobial properties and long history of use in traditional Asian medicine for stomach conditions.
Shang Tested 14 Mushroom Species Head-to-Head. Lion's Mane Won.
Most consumer articles that mention mushrooms and H. pylori focus on one species at a time. Shang and colleagues took a different approach in 2013: they tested 14 medicinal mushroom species side by side against H. pylori under identical lab conditions, making it the most comprehensive species comparison for this application in the published literature.[1]
Lion's mane showed the strongest anti-H. pylori activity of all 14 species tested. The minimum inhibitory concentration (MIC, the lowest concentration at which the extract stopped H. pylori from growing) was approximately 2 mg/mL. Other mushrooms showed measurable activity but none reached the same potency as lion's mane.
This comparative data directly answers the question "which mushroom is best for H. pylori," and yet it's almost entirely absent from consumer mushroom content. The species were tested under the same conditions, by the same research group, in the same experiment, making the ranking meaningful in a way that separate, independent studies cannot provide.
The finding that has the clearest practical relevance: lion's mane extract worked equally well against clarithromycin-resistant H. pylori strains and clarithromycin-susceptible strains.[1] Standard antibiotics work by targeting specific bacterial processes; resistance to an antibiotic means the bacteria have evolved a workaround for that specific mechanism. Lion's mane operates through a different mechanism entirely, so antibiotic resistance does not protect H. pylori from lion's mane extract.
This has obvious implications for populations where clarithromycin resistance makes standard triple therapy less reliable. For a deeper comparison of how different mushroom species measure up for stomach health, see Which Mushrooms Protect the Stomach Lining? A Comparison.
Which Part of Lion's Mane Actually Does the Work?
Knowing that lion's mane inhibits H. pylori doesn't identify what in the mushroom is responsible. That question is practically important: a whole mushroom powder product and a concentrated bioactive extract have very different pharmacological profiles, and knowing which fractions carry the anti-H. pylori activity helps determine what kind of preparation is likely to reproduce the lab results.
Liu and colleagues addressed this directly in 2016 by isolating specific fractions from Hericium erinaceus and testing each one separately against H. pylori.[2] The results showed that different fractions had different levels of anti-H. pylori potency. Not every part of the mushroom contributes equally; certain specific compounds were responsible for the antimicrobial activity, while other fractions had little or no effect.
The practical implication is that extract type matters. A lion's mane product standardized for hericenones (the primary active compounds found in the fruiting body) carries a different bioactive profile than crude whole mushroom powder. The anti-H. pylori research has been conducted on extracted fractions, not on raw mushroom material.
This doesn't mean whole mushroom powder is inert. It means that the research basis for lion's mane and H. pylori is grounded in specific extracts, and directly extrapolating those results to any commercial supplement requires acknowledging that the preparation matters; the mushroom is not a pharmacologically uniform entity. For more on lion's mane's stomach-protective mechanisms beyond H. pylori, see Lion's Mane and Stomach Health: Gastroprotective Mechanisms.
From Petri Dish to Living Animal: Wang's 1,000-Fold H. pylori Kill
In vitro MIC data shows that a compound stops bacteria from growing in a controlled dish. That's a necessary starting point. It doesn't tell you whether an orally consumed supplement can achieve a sufficient concentration in the gastric mucus layer (the physical habitat of H. pylori) to reproduce the effect. Digestion, stomach acid, absorption kinetics, and mucus barrier penetration all stand between oral consumption and bactericidal activity at the target site.
Wang and colleagues bridged this gap in 2019 by testing lion's mane ethanolic extract both in cell culture and in a living animal model using the same preparation.[3]
The in vitro results confirmed previous MIC data. The in vivo results were the new contribution: H. pylori survival in the animal model decreased by 3 log units at a concentration of 2 mg/mL. Three log units means a 1,000-fold reduction in bacterial survival. That's a substantial antimicrobial effect occurring in a living organism rather than a test tube.
Having both types of evidence from a single study matters because it rules out the possibility that the in vitro activity was an artifact of the specific lab conditions rather than a genuine property of the compound itself.
What the Wang study still cannot tell us is whether an equivalent concentration can be achieved in human gastric tissue after oral consumption of a commercially available lion's mane supplement. Animal models allow controlled dosing and tissue measurement; human pharmacokinetics are considerably more variable. The gap between an animal model result and a human clinical outcome remains open.
H. pylori Causes Stomach Cancer. Lion's Mane Has Anticancer Data. Here's the Connection.
Eradicating H. pylori reduces gastric cancer risk because the bacterium's most serious long-term consequence is not the ulcer itself. It is the cancerous progression that chronic inflammation enables. H. pylori infection triggers a sequence that researchers call the Correa cascade: normal stomach lining to chronic gastritis to intestinal metaplasia (cells that resemble intestinal cells where they don't belong) to dysplasia to gastric adenocarcinoma. This progression takes years to decades and requires sustained inflammation to drive it.
This background is why two additional studies are relevant to the H. pylori eradication story, even though neither one directly tests lion's mane against H. pylori itself.
Li and colleagues in 2014 tested Hericium erinaceus extracts against human gastrointestinal cancer cell lines in lab conditions and found significant anticancer activity across multiple extract fractions.[4] The activity was against GI cancer cells specifically, the type of cancer that H. pylori infection can eventually produce. This is a separate mechanism from the antimicrobial effect against H. pylori itself.
Kuo and colleagues in 2017 identified an additional pathway: erinacine A, a compound found specifically in lion's mane mycelium (the root-like structure of the fungus, distinct from the fruiting body), reduced gastric cancer cell viability and invasiveness in lab conditions.[5] The team used proteomic analysis, mapping the full protein landscape of the cells, to identify the specific protein changes behind the effect.
The fruiting body versus mycelium distinction matters here. Most commercial lion's mane supplements use the fruiting body, which contains hericenones. Erinacine A is a mycelium compound. A product labeled "lion's mane" may be either, and the compound profiles are genuinely different.
Neither the Li nor the Kuo study constitutes evidence that lion's mane prevents stomach cancer in people. What they establish is that multiple compounds isolated from lion's mane have direct anticancer activity against the specific cell types relevant to H. pylori-driven carcinogenesis, a preclinical foundation that informs what future clinical trials might investigate. For related research on mushrooms for gastric ulcers and their traditional use context, see Mushrooms for Gastric Ulcers: Traditional Use and Modern Evidence.
What Three Studies Can't Tell You About Natural H. pylori Treatment
The research reviewed in this article is genuinely interesting. It is also entirely preclinical, and the gap between preclinical activity and clinical efficacy in H. pylori treatment is wide enough to require honest discussion.
What the evidence establishes:
Lion's mane extracts inhibit H. pylori in controlled lab conditions across multiple independent studies. The most systematic comparison (Shang 2013) ranked it first among 14 species. The effects persist in an animal model (Wang 2019). The antimicrobial activity is not eliminated by resistance to standard antibiotics (Shang 2013). The active compounds have been partially identified (Liu 2016), and multiple fractions show direct activity against gastric cancer cells (Li 2014, Kuo 2017).
What the evidence does not establish:
Whether orally consumed lion's mane mushroom in a supplement can achieve sufficient concentration in the gastric mucus layer, where H. pylori actually lives, to produce the antimicrobial effects seen in lab conditions. H. pylori inhabits a specific ecological niche inside the mucus lining of the stomach, which is protected from the stomach lumen by physical barriers. Getting an antimicrobial compound to that location in therapeutic quantities requires more than just consuming it.
No human clinical trial has enrolled patients with confirmed H. pylori infection and tested any mushroom preparation against standard treatment or as an adjunct. This is not a minor gap; it is the entire missing piece. Without human trial data, the MIC and animal model results cannot be used to predict clinical outcomes in gastritis patients.
Where mushrooms most plausibly fit:
The most defensible role for lion's mane or other medicinal mushrooms in the H. pylori context is supporting gut health after antibiotic treatment, not replacing it. Triple therapy antibiotics are broadly disruptive to the gut microbiome; they wipe out beneficial bacteria alongside H. pylori. Mushrooms, through their beta-glucan prebiotic fibers and immune-modulating properties, may support microbiome recovery after eradication therapy. This is a different mechanism from direct antimicrobial activity, with a different evidence base, and a more tractable role.
For how lion's mane specifically interacts with intestinal immune function, see Lion's Mane and Gut Immunity: The Intestinal Immune Connection. For the full picture of how mushrooms affect H. pylori at the research level, see Mushrooms and H. pylori: Antimicrobial Activity Research.
The Bottom Line
Three independent preclinical studies show that lion's mane (Hericium erinaceus) inhibits Helicobacter pylori in lab and animal models, including antibiotic-resistant strains, at minimum inhibitory concentrations around 2 mg/mL. A 2013 comparative study found lion's mane outperformed 13 other mushroom species tested under identical conditions. The mechanism differs from antibiotic resistance pathways, which is the detail driving scientific interest in natural adjuncts. No human clinical trial has tested any mushroom for H. pylori eradication in people. The preclinical foundation is solid; the clinical chapter has not yet been written.
Frequently Asked Questions
Sources & References
- 1RTHM-00304·Shang, Xiaodong et al. (2013). “In vitro anti-Helicobacter pylori effects of medicinal mushroom extracts, with special emphasis on the Lion's Mane mushroom, Hericium erinaceus (higher Basidiomycetes)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 2RTHM-00436·Liu, Jian-Hui et al. (2016). “Anti-Helicobacter pylori activity of bioactive components isolated from Hericium erinaceus..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
- 3RTHM-00592·Wang, Ge et al. (2019). “In Vitro and In Vivo Inhibition of Helicobacter pylori by Ethanolic Extracts of Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 4RTHM-00614·Li, Guang et al. (2014). “Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
- 5RTHM-00884·Kuo, Hsing-Chun et al. (2017). “A Comparative Proteomic Analysis of Erinacine A's Inhibition of Gastric Cancer Cell Viability and Invasiveness..” Cellular physiology and biochemistry : international journal of experimental cellular physiology.Study breakdown →PubMed →↩